rs121908436
Positions:
Variant summary
Our verdict is Pathogenic. Variant got 14 ACMG points: 14P and 0B. PM2PP3_StrongPP5_Very_Strong
The NM_014112.5(TRPS1):c.2795C>T(p.Ala932Val) variant causes a missense change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. 12/21 in silico tools predict a damaging outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★).
Frequency
Genomes: not found (cov: 32)
Consequence
TRPS1
NM_014112.5 missense
NM_014112.5 missense
Scores
15
2
2
Clinical Significance
Conservation
PhyloP100: 9.75
Genes affected
TRPS1 (HGNC:12340): (transcriptional repressor GATA binding 1) This gene encodes a transcription factor that represses GATA-regulated genes and binds to a dynein light chain protein. Binding of the encoded protein to the dynein light chain protein affects binding to GATA consensus sequences and suppresses its transcriptional activity. Defects in this gene are a cause of tricho-rhino-phalangeal syndrome (TRPS) types I-III. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 14 ACMG points.
PM2
Very rare variant in population databases, with high coverage;
PP3
MetaRNN computational evidence supports a deleterious effect, 0.99
PP5
Variant 8-115418358-G-A is Pathogenic according to our data. Variant chr8-115418358-G-A is described in ClinVar as [Pathogenic]. Clinvar id is 5578.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
TRPS1 | NM_014112.5 | c.2795C>T | p.Ala932Val | missense_variant | 6/7 | ENST00000395715.8 | NP_054831.2 | |
TRPS1 | NM_001282903.3 | c.2774C>T | p.Ala925Val | missense_variant | 6/7 | NP_001269832.1 | ||
TRPS1 | NM_001282902.3 | c.2768C>T | p.Ala923Val | missense_variant | 5/6 | NP_001269831.1 | ||
TRPS1 | NM_001330599.2 | c.2756C>T | p.Ala919Val | missense_variant | 5/6 | NP_001317528.1 |
Ensembl
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD3 genomes
Cov.:
32
GnomAD4 exome Cov.: 31
GnomAD4 exome
Cov.:
31
GnomAD4 genome Cov.: 32
GnomAD4 genome
Cov.:
32
ClinVar
Significance: Pathogenic
Submissions summary: Pathogenic:5Other:1
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not provided Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Dec 01, 2023 | TRPS1: PM1, PM2, PM5, PS2:Moderate, PS4:Moderate, PP3 - |
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Aug 24, 2022 | Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant does not alter protein structure/function; This variant is associated with the following publications: (PMID: 27706911, 25792522, 24502542, 18946009, 11950061, 28468609, 30541476, 30143558, 28426188) - |
Trichorhinophalangeal syndrome, type III Pathogenic:1
Pathogenic, no assertion criteria provided | literature only | OMIM | Jan 01, 2002 | - - |
Congenital anomaly of kidney and urinary tract Pathogenic:1
Likely pathogenic, no assertion criteria provided | literature only | Yale Center for Mendelian Genomics, Yale University | Aug 24, 2018 | - - |
Trichorhinophalangeal dysplasia type I;C1860823:Trichorhinophalangeal syndrome, type III Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jul 30, 2022 | This sequence change replaces alanine, which is neutral and non-polar, with valine, which is neutral and non-polar, at codon 932 of the TRPS1 protein (p.Ala932Val). For these reasons, this variant has been classified as Pathogenic. This variant disrupts the p.Ala932 amino acid residue in TRPS1. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 11112658, 30541476). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt TRPS1 protein function. ClinVar contains an entry for this variant (Variation ID: 5578). This missense change has been observed in individuals with tricho-rhino-phalangeal syndrome (PMID: 18946009, 24502542). It has also been observed to segregate with disease in related individuals. This variant is not present in population databases (gnomAD no frequency). - |
Trichorhinophalangeal dysplasia type I Other:1
not provided, no classification provided | literature only | GeneReviews | - | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Pathogenic
CADD
Pathogenic
DANN
Pathogenic
DEOGEN2
Uncertain
D;.;D;.;.
Eigen
Pathogenic
Eigen_PC
Pathogenic
FATHMM_MKL
Uncertain
D
LIST_S2
Pathogenic
D;D;.;D;D
M_CAP
Pathogenic
D
MetaRNN
Pathogenic
D;D;D;D;D
MetaSVM
Pathogenic
D
MutationAssessor
Pathogenic
H;.;H;.;.
PrimateAI
Pathogenic
D
PROVEAN
Benign
.;N;N;N;N
REVEL
Pathogenic
Sift
Pathogenic
.;D;D;D;D
Sift4G
Pathogenic
.;D;D;D;D
Polyphen
D;D;D;.;D
Vest4
0.74, 0.95, 0.93, 0.78
MutPred
Gain of MoRF binding (P = 0.1805);.;Gain of MoRF binding (P = 0.1805);.;.;
MVP
0.89
MPC
1.6
ClinPred
D
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at